Scarica l'app Stockscreener
72.08
0.24%
-0.17
Dopo l'orario di chiusura:
72.08
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Forum
Previsione
Frazionamento azionario
Storia dei dividendi
Precedente Chiudi:
$72.25
Aprire:
$72.28
Volume 24 ore:
3.77M
Relative Volume:
0.83
Capitalizzazione di mercato:
$11.30B
Reddito:
$1.21B
Utile/perdita netta:
$109.52M
Rapporto P/E:
103.53
EPS:
0.6962
Flusso di cassa netto:
$269.60M
1 W Prestazione:
-0.51%
1M Prestazione:
-0.06%
6M Prestazione:
+36.46%
1 anno Prestazione:
+41.44%
Intervallo 1D:
$72.08
$72.33
Intervallo di 1 settimana:
$72.08
$72.48
Portata 52W:
$43.20
$72.62
Bio Techne Corp Stock (TECH) Company Profile
Nome
Bio Techne Corp
Settore
Industria
Telefono
612-379-8854
Indirizzo
614 MCKINLEY PL N E, MINNEAPOLIS, MN
Compare TECH vs VRTX, REGN, ARGX, MRNA, RVMD
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
TECH
Bio Techne Corp
|
72.08 | 11.33B | 1.21B | 109.52M | 269.60M | 0.6962 |
VRTX
Vertex Pharmaceuticals Inc
|
514.56 | 132.08B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
793.26 | 83.15B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
984.04 | 62.71B | 4.16B | 1.29B | 734.26M | 19.58 |
MRNA
Moderna Inc
|
136.62 | 54.14B | 2.23B | -3.19B | -1.60B | -8.1462 |
RVMD
Revolution Medicines Inc
|
203.35 | 44.51B | 742.00K | -1.37B | -1.07B | -7.0731 |
Bio Techne Corp Stock (TECH) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-09-03 | Aggiornamento | RBC Capital Mkts | Sector Perform → Outperform |
| 2025-08-21 | Aggiornamento | Citigroup | Neutral → Buy |
| 2025-07-22 | Ripresa | Stephens | Overweight |
| 2025-07-09 | Iniziato | TD Cowen | Buy |
| 2025-05-30 | Iniziato | Wells Fargo | Overweight |
| 2025-04-09 | Downgrade | KeyBanc Capital Markets | Overweight → Sector Weight |
| 2025-03-18 | Iniziato | Evercore ISI | Outperform |
| 2025-02-19 | Downgrade | Robert W. Baird | Outperform → Neutral |
| 2024-05-22 | Downgrade | Citigroup | Buy → Neutral |
| 2024-02-08 | Iniziato | Scotiabank | Sector Outperform |
| 2024-02-02 | Downgrade | Stifel | Buy → Hold |
| 2023-12-07 | Iniziato | UBS | Buy |
| 2023-08-28 | Iniziato | William Blair | Outperform |
| 2023-01-10 | Aggiornamento | Wells Fargo | Underweight → Equal Weight |
| 2022-12-14 | Iniziato | Deutsche Bank | Buy |
| 2022-12-12 | Aggiornamento | Citigroup | Neutral → Buy |
| 2022-12-07 | Iniziato | RBC Capital Mkts | Sector Perform |
| 2022-08-25 | Iniziato | Credit Suisse | Outperform |
| 2022-04-25 | Downgrade | Wells Fargo | Equal Weight → Underweight |
| 2021-09-15 | Aggiornamento | KeyBanc Capital Markets | Sector Weight → Overweight |
| 2021-03-08 | Aggiornamento | Stephens | Equal-Weight → Overweight |
| 2021-02-23 | Aggiornamento | Stifel | Hold → Buy |
| 2021-01-25 | Reiterato | The Benchmark Company | Buy |
| 2020-11-10 | Iniziato | KeyBanc Capital Markets | Sector Weight |
| 2020-09-30 | Iniziato | Atlantic Equities | Overweight |
| 2020-07-15 | Downgrade | Stephens | Overweight → Equal-Weight |
| 2020-05-27 | Downgrade | Stifel | Buy → Hold |
| 2020-05-14 | Iniziato | The Benchmark Company | Buy |
| 2020-01-08 | Ripresa | Stephens | Overweight |
| 2020-01-08 | Iniziato | Wells Fargo | Equal Weight |
| 2020-01-07 | Iniziato | Citigroup | Neutral |
| 2019-11-15 | Iniziato | Stifel | Buy |
| 2019-07-02 | Aggiornamento | Janney | Neutral → Buy |
| 2019-01-14 | Aggiornamento | Stephens | Equal-Weight → Overweight |
| 2018-10-31 | Downgrade | Craig Hallum | Buy → Hold |
| 2018-10-17 | Iniziato | Goldman | Neutral |
| 2018-06-15 | Iniziato | Argus | Buy |
| 2017-07-13 | Iniziato | Wells Fargo | Market Perform |
| 2017-02-09 | Iniziato | Citigroup | Buy |
| 2017-01-18 | Iniziato | Deutsche Bank | Buy |
| 2016-11-10 | Ripresa | Leerink Partners | Outperform |
| 2015-01-21 | Reiterato | Robert W. Baird | Outperform |
| 2013-09-20 | Aggiornamento | Robert W. Baird | Neutral → Outperform |
Mostra tutto
Bio Techne Corp Borsa (TECH) Ultime notizie
$HAREHOLDER ALERT: The M&A Class Action Firm Continues to Investigate the Merger – AUUD, TECH, CZR and CBAN - GlobeNewswire Inc.
TECH: Bio-Techne Corp Latest Stock Price, Analysis, News and Trading Ideas - Stocktwits
Research Use Recombinant Protein Market Report Now Available — Forecasts Market Growth from $1.11B (2026) to $1.55B by 2031, Profiling Thermo Fisher, Bio-Techne, Merck KGaA, Danaher, Revvity, and Others - Yahoo Finance UK
Bio-Techne Corp (TECH) Stock Analysis: Navigating Its Current Valuation and Growth Potential - DirectorsTalk Interviews
Bio-Techne Corp (NASDAQ: TECH) Share Price, TECH Stock News, TECH Share Price & Updates - Kalkine
Ademi LLP investigates Bio-Techne sale to Merck KGaA - scanx.trade
Global Multiplex Assays Market 2026 Edition - GlobeNewswire Inc.
Bio-Techne Corp (TECH) Technical Analysis: Support, Resistance, Indicators & Moving Averages - tradingkey.com
Bio-Techne (TECH), What Is Behind The Latest Attention? - simplywall.st
Bio-Techne Achieves Science Based Targets Validation and Reports Significant Progress Toward Climate Goals - marketscreener.com
Legal & General buys $19.51M stake in Bio-Techne - Dealroom
Bio-Techne Corp (TECH) Stock Analysis: Evaluating the Balance Between Growth Potential and Current Valuation - DirectorsTalk Interviews
Winners And Losers Of Q2: Bio-Techne (NASDAQ:TECH) Vs The Rest Of The Research Tools & Consumables Stocks - Yahoo Finance
Bio-Techne Corp (TECH) Financials – Balance Sheet, Profit & Loss, Cash Flow - Value Research
Bio-Techne To Be Acquired by Merck KGaA - Morningstar
Bio-Techne draws fresh institutional cash as revenue climbs to $321M - app.dealroom.co
BIO-TECHNE Corp FY 2026: Revenue $1.22B, EPS $1.16— 10-K Summary - TradingView
Bio-Techne Gives FTC More Time On $11.3B Merck Deal - Law360
Is Bio-Rad a Buy as Digital PCR Growth Meets a Premium Valuation? - TradingView
Bio-Techne (Nasdaq: TECH) investors to vote on Merck cash takeover - Stock Titan
Bio-Techne (NASDAQ: TECH) GC gets new RSU grants, no stock sales - Stock Titan
Bio-Techne (NASDAQ: TECH) grants CFO 22,438 and 36,459 RSUs - Stock Titan
Bio-Techne (TECH) director granted 1,381 RSUs vesting 2027-29 - Stock Titan
Bio-Techne (TECH) insider updates stock holdings - Stock Titan
Bio-Techne (NASDAQ: TECH) grants president 8,702 and 14,140 RSUs - Stock Titan
Benchmark reiterates Hold stock rating on Bio-Techne after Q4 results - Investing.com India
BIO-TECHNE Executive Steven C. Crouse Files Form 4 After RSU Vesting and Share Withholding - Kalkine Media
Bio-Techne (TECH) CEO exercises awards, 10.8K shares withheld - Stock Titan
Bio-Techne (TECH) CFO exercises awards, covers taxes in stock - stocktitan.net
Bio-Techne (NASDAQ: TECH) exec updates option and RSU holdings - Stock Titan
Bio-Techne (TECH) GC sees RSUs vest, others forfeited on equity awards - Stock Titan
Bio-Techne (TECH) awards give executive 5,423 shares, 1,947 withheld - Stock Titan
Bio-Techne (TECH) director exercises 589 RSUs, uses shares for taxes - Stock Titan
symbol__ Stock Quote Price and Forecast - CNN
Is Wall Street Bullish or Bearish on Bio-Techne Stock? - Yahoo Finance
Bio-Techne (TECH) Holds Steady at $72.39 as Shares Consolidate Between $68.77 Support and $76.01 ResistanceKey Reversal Day - vinanet.vn
Bio-Techne (TECH) Holds Steady at $72.40 as Life Sciences Sector Digests Mixed SignalsOption Strike Build - vinanet.vn
S&CO Inc. Buys Shares of 76,614 Bio-Techne Corp $TECH - MarketBeat
TECH Q2 2026 Earnings: EPS Misses Consensus, Shares Edge HigherMargin Guidance - vinanet.vn
TECH Q2 2026 Earnings: EPS Misses Consensus by 3.34% as Shares Edge HigherSaaS Earnings Trends - vinanet.vn
Bio-Techne Corp (TECH) Stock News Today - tradingkey.com
Wells Fargo Initiates Bio-Techne(TECH.US) With Hold Rating, Announces Target Price $73 - Moomoo
Bio-Techne's Fiscal Q4 Organic Revenue Growth Consistent With Progressive Improvement Story, RBC Says - marketscreener.com
Bio-Techne (NASDAQ:TECH) Downgraded to Equal Weight Rating by Wells Fargo & Company - MarketBeat
Bio-Techne (NASDAQ:TECH) Dividend Move Sparks Fresh Attention - Kalkine Media
TECH Q4 Earnings Meet Estimates, Revenues Surpass, Stock Rises - The Globe and Mail
Bio-Techne Keeps Quarterly Dividend at $0.08 a Share, Payable Aug. 28 to Shareholders of Record as of Aug. 24 - marketscreener.com
Bio-Techne Corp (NASDAQ:TECH) to Issue Dividend Increase$0.65 Per Share - MarketBeat
Bio-Techne Dividend Payable Aug. 28 After Record-Date Correction - Stock Titan
Bio-Techne Corp to Issue Quarterly Dividend of $0.08 (NASDAQ:TECH) - MarketBeat
Bio-Techne (NASDAQ:TECH) Releases Earnings Results, Meets Estimates - MarketBeat
Bio Techne Corp Azioni (TECH) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
3.04%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):